Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1830 studies found for:    Blood Coagulation Disorders: Clinical Trials
Show Display Options
Rank Status Study
1 Completed Hemodilution and Coagulopathy With 3 Colloids
Condition: Dilutional Coagulopathy
Intervention: Other: Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)
2 Recruiting Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT)
Condition: Blood Coagulation Disorders
Intervention: Biological: Frozen plasma
3 Terminated RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma
Condition: Major Trauma
Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate;   Drug: Fresh Frozen Plasma blood type 0, A, B and AB
4 Recruiting Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency
Condition: Benign Prostatic Hyperplasia
Interventions: Procedure: HoLEP;   Procedure: Greenlight laser PVP
5 Completed Changes in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial
Condition: Blood Coagulation Disorders
Intervention: Behavioral: Changes on Oral Vitamin K Intake
6 Completed Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: 40K PEG-rFIX
7 Active, not recruiting A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
8 Completed Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
9 Recruiting Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions
Condition: Coagulopathy
Interventions: Device: ROTEM;   Drug: Cryoprecipitate;   Drug: RiaSTAP
10 Recruiting Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)
Conditions: Wounds and Injuries;   Acute Coagulopathy
Interventions: Drug: Tranexamic Acid;   Drug: Placebo
11 Completed Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
12 Completed Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency;   Healthy
Interventions: Drug: catridecacog;   Drug: recombinant factor XIII
13 Not yet recruiting PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
Conditions: Bleeding;   Blood Loss, Surgical;   Cardiovascular Surgical Procedures;   Prothrombin Complex Concentrates;   Fresh Frozen Plasma
Interventions: Drug: Prothrombin complex concentrate (Human);   Biological: Fresh frozen plasma (FFP)
14 Unknown  "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
Conditions: Myocardial Ischemia;   Blood Coagulation Disorders;   Coronary Artery Disease;   Heart Valve Diseases
Intervention: Drug: Recombinant Activated Factor VII
15 Completed
Has Results
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
Conditions: Blood Coagulation Disorders;   Hemophilia A
Interventions: Biological: Recombinant Factor VIII (BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
16 Completed Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
17 Completed Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
18 Completed
Has Results
Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
19 Completed A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
20 Completed Dose Response to Recombinant Factor VIIa When Administered for Bleed
Conditions: Congenital Bleeding Disorder;   Healthy
Intervention: Drug: activated recombinant human factor VII

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.